What the decision means for a cell therapy for spinal cord injury
Japan granted full marketing approval to Stemirac on November 16, 2026, after nearly eight years of conditional approval. Stemirac uses cells from a patient’s own bone marrow to treat neurological symptoms and functional problems associated with certain spinal cord injuries. The decision changes the product’s status in Japan. It does not authorize it in the United States or establish that it can reverse a spinal cord injury. [1, 2, 7]
Why the decision matters
Stemirac is Japan’s first regenerative medicine product to move from time-limited conditional approval to full approval. The original decision allowed it to be used under specific conditions while more evidence was collected. An advisory committee backed full approval in October, but the decision came in November. [1–4]
The path to full approval
| Date | What happened |
|---|---|
| December 28, 2018 | Japan granted time-limited approval and required further evaluation. [2, 4] |
| November 14, 2025 | Nipro applied for full approval after evaluating outcomes in treated and untreated patients. [1, 2] |
| October 15, 2026 | A health ministry committee endorsed full approval. The decision was not yet final. [3] |
| November 16, 2026 | Japan granted full marketing approval. [1, 2] |
The evidence Japan reviewed
The original regulator review describes an exploratory study of 13 treated patients at one hospital. With no control group in that study, it was hard to separate the treatment’s effect from recovery that might have happened anyway. For the later evaluation, Nipro compared outcomes with those of patients outside the treated group. This was not a randomized head-to-head trial. [1, 4, 5]
The new announcements confirm the approval but do not provide the full comparative results or detailed safety outcomes. They cannot tell someone how much extra improvement to expect. An improvement on a spinal cord injury scale also does not necessarily mean someone will walk again or regain independence. [1, 2, 4]
What the approval does not change
Earlier Japanese regulator documents describe use in selected patients with traumatic spinal cord injuries. The updated full-approval label was not located for this report. Sapporo Medical University says treatment will continue at equipped facilities in Japan. This decision does not establish a benefit for longstanding injuries or show that other stem cell products offer the same results. [2, 4, 6, 7]
Related reading: Japan’s post-approval study for a Parkinson’s cell therapy
